secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001213900-23-079677
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial recasts 2022 and 2021 financials to reflect Purnovate discontinued ops after sale
--------------------------------------------------------------------------------

- Completed sale of Purnovate assets and business to Adovate, LLC on June 30, 2023.
- Historical Purnovate results now shown as discontinued operations for 2022 and 2021.
- Only Item 7 (MD&A) and Item 8 (Financial Statements) are revised; other 10-K sections unchanged.
- Company directs investors to Q1 and Q2 2023 Form 10-Qs for more recent developments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023079677/0001213900-23-079677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023079677/ea185608-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-079677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer